Last reviewed · How we verify
NCT07196033: AGBR-FERN-Gyn
Asian Gynecological Brachytherapy Registry in Cervical Cancer
trial in Stage IIIA Cervical Cancer FIGO 2018 in 1,000 participants. Currently enrolling.
15 March 2028
Quick facts
| Lead sponsor | Tata Memorial Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 20 February 2026 |
| Primary completion | 15 March 2028 |
| Estimated completion | 20 May 2028 |
| Sites | 5 locations across Japan, Thailand, India |
Conditions studied
- Stage IIIA Cervical Cancer FIGO 2018 — all drugs for Stage IIIA Cervical Cancer FIGO 2018 →
- Stage IIIB Cervical Cancer FIGO 2018 — all drugs for Stage IIIB Cervical Cancer FIGO 2018 →
- Stage IVA Cervical Cancer FIGO 2018 — all drugs for Stage IVA Cervical Cancer FIGO 2018 →
- Stage IB Cervical Cancer FIGO 2018 — all drugs for Stage IB Cervical Cancer FIGO 2018 →
Sponsor
Tata Memorial Hospital
Who can join
Eligibility, female only, with Stage IIIA Cervical Cancer FIGO 2018 or Stage IIIB Cervical Cancer FIGO 2018. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Gynecological cancer poses as significant public health issue, especially in Asian countries, where it is a leading cause of cancer-related deaths among women. Cervical cancer accounts for around 311,000 deaths annually, with over 85% occurring in low- and middle-income nations, primarily in Asia. Factors contributing to this burden include limited access to preventive care, inadequate screening, high rates of human papillomavirus infection, and cultural barriers that delay medical attention. For patients with advanced cervical cancer, the standard treatment involves external beam radiation therapy along with chemotherapy followed by internal radiation, known as Brachytherapy. This technique uses unique set of devices placed internally at the tumor sitegiving localized radiation to the residual tumor tissue. While advanced brachytherapy techniques have been developed and practiced in Europe and American countries yielding excellent clinical outcomes, there is insufficient data on the use and results of such advanced brachytherapy techniques in Asian populations, leading to a lack of standardized practices. To address these issues, the Asian Gynecological Brachytherapy Registry (ABGR) has been established as a collaborative platform for data collection and analysis on the use of Brachytherapy techniques. This registry aims to consolidate information from various healthcare settings across Asia, enhancing understanding of cervical cancer's epidemiology, evaluating treatment effectiveness, and identifying areas for improvement in patient care.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07196033
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stage IIIA Cervical Cancer FIGO 2018
Currently open trials in the same condition.
- NCT07061977 — Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance C · Phase 3 · recruiting
- NCT05722288 — Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in · Phase 2 · recruiting
- NCT04574635 — Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer · active not recruiting
- NCT04580771 — A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial · Phase 2 · active not recruiting
- NCT04622670 — Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Pat · NA · active not recruiting
Other Tata Memorial Hospital trials
Trials by the same sponsor.
- NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
- NCT06804135 — Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer · recruiting
- NCT07435623 — Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study · recruiting
- NCT07342231 — FAPi PET in Pancreatic Ductal Adenocarcinoma · recruiting
- NCT07354087 — Impact of Molecular Pathological And Clinical Features for Adjuvant Treatment Selection in Endometrial Cancer: Asian Reg · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07196033 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tata Memorial Hospital
- Last refreshed: 9 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07196033.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing